Restoring the Efficacy of Chemotherapy: Utilizing CRISPR as a Gene- Disabling Treatment for Squamous Cell Carcinoma of the Lung

Time: 4:30 pm
day: Day One


  • Understanding the science behind disabling the NRF2 gene as a squamous cell carcinoma treatment adjunct
  • Evaluating the efficacy and safety data, and how these are being demonstrated to the regulators to transition to clinical development
  • Exploring the differences and potential benefits in developing a gene editing product in a community-based health system